Comparison of top 10 best-selling anti-tumor drugs in China and the United States in 2019.

Recently, relevant advisory bodies in the industry announced the top ten best-selling anti-tumor drugs in China and the United States in 2019.
from the drug category, the gap between China and the United States is large.
2019, the top ten best-selling anti-tumor drugs in the United States are innovative, while four of China's top 10 best-selling anti-tumor drugs are traditional chemotherapy drugs.
can also be reflected in the side, China's top ten best-selling anti-tumor drugs upgrade space is huge, the future will be more innovative drugs to replace traditional chemotherapy drugs and into the list.
in terms of innovation, overseas pharmaceutical giants are crushing local pharmaceutical companies.
America's top ten best-selling anti-tumor drug research and development drug companies are Mercado, Roche, BMS, AbbVie, Pfizer, these overseas pharmaceutical giants, the same, China's top ten best-selling anti-tumor drugs are mostly divided between these giants, only atrotinie stand out as the only domestic drug on the list.
From the time of market, the top ten best-selling drugs in the United States to promote an average of 5 years to enter the Chinese market, and in 2019 the top ten best-selling anti-tumor drugs in the United States, to the amine, deshu single anti-U.S. market, it took more than 5 years to enter China, in addition, as a treatment of multiple myeloma (MM) heavy drug Pomadoamine has not yet entered China.
From the point of view of cancer species, China and the United States top ten best-selling anti-tumor drugs, no drugs were approved only one adaptive disorder, are approved multiple adaptive disorders, such as the last five years of the hot PD-1 single anti-double brake, Paboli pearl single anti-There are more than a dozen adaptive disorders in Navuliyu monoanti, and the only domestic drug on the list, atrotinib, is no exception, in addition to approved non-small cell lung cancer, small cell lung cancer and soft tissue sarcoma, but also in the layout of thyroid cancer and other adaptations.
from this point of view, an anti-tumor drug to sell well, ADHD layout is Wang Dao.
Top 10 Best-Selling Anti-Tumor Drugs in the U.S. in 2019 (Source: Forward-Looking Industrial Research Institute, Pomadamine not yet available in China) China's top 10 best-selling anti-tumor drugs in 2019 (Source: Forward-Looking Industrial Research Institute, U.S.A.) According to Frost Sullivan Data, 20 The global drug market CAGR is expected to be about 5% in 19-2023, about $1.6 trillion in 2023, about 11% in the global market for anti-tumor drugs, and $250 billion in 2023, accounting for 16% of the global drug market, significantly faster than the global drug market.
rapid development of the global anti-tumor drug market, the Chinese market is growing faster.
2019-2023, China's drug market CAGR of about 7%, in 2023 reached 322 billion U.S. dollars, China's anti-tumor drug market CAGR of 14%, in 2023 reached 45 billion U.S. dollars, accounting for 14% of China's drug market, significantly higher than the growth rate of the global cancer market.
and the future growth rate of China's anti-tumor drug market may be further improved, mainly for three reasons.
1, China's demand for anti-tumor drugs is increasing, the market size is expanding.
according to the statistics of the National Cancer Center, the number of new cancer patients in China in 2010 was 235.23 per 100,000, in 2015 it was 285.83 per 100,000, and in five years CAGR reached 3.97%.
addition, the five-year survival rate for cancer patients in China was 37.20 percent in 2015, compared with 67 percent in the United States.
there is a lot of room for improvement in the five-year survival rate of cancer patients in China.
the number of cancer patients in need of medication in China is expected to continue to grow in the future.
2, China's treatment of malignant tumors mainly chemotherapy, so better efficacy of immunotherapy and targeted treatment penetration increase is inevitable.
addition, the prevalence of immunotherapy and targeted therapy is expected to generally extend the survival rate of cancer patients, the stock of drug demand may expand.
3, the policy to encourage anti-tumor innovative drugs to participate in health care negotiations, the future access to anti-tumor innovative drugs is expected to be greatly enhanced.
from this point of view, in the long run, China's top ten best-selling anti-tumor drugs will also be updated, I believe that more and more innovative drugs on the list, and will be more and more in line with the U.S. list.
.